10Dec 2017

THE NEW AGE SAVIOUR FOR COMBATING CANCER: ANTIBODY DRUG CONJUGATES.

  • Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh-201313.
  • Department of Pharmaceutics, Jamia Hamdard, Hamdard University-110062.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Traditional techniques opted to treat cancer were found to be extremely harmful to the tissues when given at a slightly higher dose. ADCs (Antibody Drug Conjugates) have transformed the field of cancer chemotherapy. ADCs use monoclonal antibodies (mAbs) to explicitly tie tumour-related target antigens and convey an exceptionally powerful cytotoxic agent. The synergistic mix of mAbs conjugated too little molecule chemotherapeutics, through a stable linker, has given rise to an adequate class of anti-cancer drugs with an effectively extensive and quickly developing clinical pipeline. Antibody drug conjugates (ADCs) are an important division of therapeutics that allows the antigen-selective ability of mAbs to deliver highly potent cytotoxic drugs at the site of antigen-expressing tumor cells. The utilization of mAb coordinated delivery can present a high therapeutic index to exceptionally strong cytotoxic drugs, expanding both the efficacy and level of safety of the treatment. In other words, to achieve the goal of highly improved therapeutic efficacy and reduced toxicity, each component of an ADC i.e. the mAb, linker and the drug needs to be considered in context of targeted antigen. Furthermore, the mechanism of ADCs, characteristics of targets, methods of preparation, linker drugs being used in ADC design and regulatory requirements for new drug approval are discussed.

  1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer.?Nat Biotechnol.?2005; 23:1147?57.
  2. Ado-trastuzumab emtansine (U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute)?.
  3. Agarwal P, Bertozzi CR (2015)?Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development.?Bioconjug Chem26(2): 176?192.
  4. Allen TM. Ligand-targeted therapeutics in anticancer therapy.?Nat Rev Cancer.?2002; 2:750?63.
  5. Bird, R. E., et al., Science, 242: 423-426 (1988)
  6. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM (2011)?SAR3419: an anti-CD19-Maytansinoid immunoconjugate for the treatment of B-cell malignancies.?Clin Cancer Res17(20): 6448?6458.
  7. Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK (2008)?Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.?Cancer Chemother Pharmacol61(6): 1027?1035
  8. Borrebaeck, Journal of Immunological Methods, vol. 123, pp. 157 165 (1989).
  9. Brentuximab vedotin (SGN35), ADC Review/Journal of Antibody-drug Conjugates
  10. Christina Peters and Stuart Brown, Antibody?drug conjugates as novel anti-cancer Chemotherapeutics, 35(2015), 1-20.
  11. Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M, Lazzari P, Shankar S, Sani M, Zanda M, van Dongen GA (2014)?Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.?Cancer Res74(20): 5700?5710.
  12. FDA Approves Genentech's Kadcyla? (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer
  13. FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market, US FDA
  14. Flygare JA, Pillow TH, Aristoff P (2013)?Antibody-drug conjugates for the treatment of cancer.?Chem Biol Drug Des81(1): 113?121.
  15. Funaro, A.L. Horenstein, P. Santoro, C. Cinti, A. Gregorini, F. Malavasi, Monoclonal antibodies and therapy of human cancers, Biotechnol. Adv. 18 (5) (2000) 385?401.
  16. Gupta PB, Chaffer CL, Weinberg RA (2009)?Cancer stem cells: mirage or reality??Nat Med15(9): 1010?1012.
  17. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains.?Nat Biotechnol.?2005; 23:1126?36.
  18. http://www.ddfevent.com/wp-content/uploads/2017/03/Carsten-Olbrich.pdf
  19. Husain Attarwala, Role of antibodies in cancer targeting, 1(1) (2010), 53-56.
  20. M. Lambert, Drug-conjugated monoclonal antibodies for treatment of cancer, Curr. Opin. Pharmacol. 5 (5) (2005) 543?549.
  21. Lambert JM, Drug-conjugated antibodies for the treatment of cancer, 76 (2) (2013), 248-62.
  22. Cegnar, J. Kos, J. Kristl, Cystatin incorporated in poly (lactide-coglycolide) nanoparticles: development and fundamental studies on preservation of its activity, Eur. J. Pharm. Sci. 22 (5) (2004) 357?364.
  23. C. Garnett, Targeted drug conjugates: principles and progress, Adv. Drug Del. Rev. 53 (2) (2001) 171?216.
  24. Mack F, Ritchie M, Sapra P (2014)?The next generation of antibody drug conjugates.?Semin Oncol41(5): 637?652.
  25. Moldenhauer G, Salnikov AV, Luttgau S, Herr I, Anderl J, Faulstich H (2012)?Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.?J Natl Cancer Inst104(8): 622?634.
  26. Nikolaos Diamantis, Udai Banerji (2016) Antibody-drug conjugates- an emerging class of cancer treatment. British journal of cancer. 114(4):362-367.
  27. Osband, et al., Immunology Today, vol. 11, No. 6, pp. 193-195 (1990).
  28. Sapra, T.M. Allen, Ligand-targeted liposomal anticancer drug, Prog. Lipid Res. 42 (5) (2003) 439?462.
  29. A. Trail, A.B. Bianchi, Monoclonal antibody drug conjugates in the treatment of cancer, Curr. Opin. Immunol. 11 (5) (1999) 584?588.
  30. A. Trail, H.D. King, G.M. Dubowchik, Monoclonal antibody drug immunoconjugates, Cancer Immunol. Immunother. 52 (5) (2003) 328?337.
  31. Palakurthi S (2015)?Challenges in SN38 drug delivery: current success and future directions.?Expert Opin Drug Deliv27: 1?11.
  32. Pamela A. Trail, Antibody Drug Conjugates as Cancer Therapeutics, 2(2013) 113-129.
  33. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR (2014)?Site-specific antibody drug conjugates for cancer therapy.?MAbs6(1): 34?45.
  34. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014)?Antibody-drug conjugates: current status and future directions.?Drug Discov Today19(7): 869?881.
  35. Petra Kocbek, Nata?a Obermajer, Mateja Cegnar, Janko Kos, Julijana Kristl, Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, 120(2007), 18-26.
  36. Russell L. Barton,?Deborah L. Guttman-Carlisle,?Gary A. Koppel, US5665358 A, Sep 9, 1997, US 08/649,568.
  37. Jaracz, J. Chen, L.V. Kuznetsova, I. Ojima, Recent advances in tumourtargeting anticancer drug conjugates, Bio. Med. Chem. 13 (17) (2005), 5043?5054.
  38. Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP (2013)?Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.?Mol Cancer Ther12(1): 38?47.
  39. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP (2011)?Investigational antibody drug conjugates for solid tumors.?Expert Opin Invest Drugs20(8): 1131?1149.
  40. Sapra P, Shor B (2013)?Monoclonal antibody-based therapies in cancer: advances and challenges.?Pharmacol Ther138(3): 452?469.
  41. Shefet-Carasso L, Benhar I (2015)?Antibody-targeted drugs and drug resistance-Challenges and solutions.?Drug Resist Updat18: 36?46.
  42. Siler Panowski,?Sunil Bhakta,?Helga Raab,?Paul Polakis&?Jagath R Junutula, Site-specific antibody drug conjugates for cancer therapy, 6(1) (2014), 34-45.
  43. Smaglo, B.G., Aldeghaither, D. and Weiner, L.M. (2014). The development of immunoconjugates for targeted cancer therapy. Nat. Rev. Clin Oncol. 11, 637?648.
  44. Spalding, Bio/Technology, vol. 11, pp. 428-429 (1993).
  45. Stephen Ornes (2013) antibody-drug conjugates. Proc Nati Acad Sci U S A.110 (34):13695.
  46. M. Fahmy, P.M. Fong, A. Goyal, W.M. Saltzman, Targeted for drug delivery, Mater. Today 8 (8) (2005) 18?26.
  47. Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W (2009)?A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of?in vitroselectivity, activity and stability.?Leukemia?23(8): 1389?1397.
  48. Thery JC, Spano JP, Azria D, Raymond E, Penault Llorca F. Resistance to human epidermal growth factor receptor type 2-targeted ?therapies. Eur J Cancer. 2014?Mar;50(5):892-901
  49. Van Herpen CM, Banerji U, Mommers EC, Koper NP, Goedings P, Lopez J, Awada A, Fiebrich HB, Aftimos PG (2015)?Phase I Dose-Escalation Trial with the DNA-Alkylating Anti-HER2 Antibody-Drug Conjugate SYD985. European Cancer Congress: Vienna, Austria.
  50. Verma S, et al. EMILIA Study Group Trastuzumab emtansine for HER2-positive advanced breast cancer.?N Engl J Med.?2012;367(19):1783?1791.
  51. Younes A, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin?s lymphoma.?J Clin Oncol.?2012;30(18):2183?2189.

[Mehak Chauhan, Nikita Sehgal and Kriti Soni. (2017); THE NEW AGE SAVIOUR FOR COMBATING CANCER: ANTIBODY DRUG CONJUGATES. Int. J. of Adv. Res. 5 (Dec). 22-36] (ISSN 2320-5407). www.journalijar.com

Kriti Soni
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard University, Hamdard Nagar, New Delhi 110062, India.

DOI:

Article DOI: 10.21474/IJAR01/5933      
DOI URL: https://dx.doi.org/10.21474/IJAR01/5933

Download Full Paper

Download PDF No. of Downloads: 25 | No. of Views: 186